Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674448 | 0.81 | TSHR (0.35) | TSHRCES1DAGLANOTUMRAB9A | |
| SCHEMBL14446927 | 0.76 | — | — | |
| SCHEMBL21469421 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL7556827 | 0.71 | — | — | |
| SCHEMBL10328385 | 0.67 | — | — | |
| SCHEMBL30674447 | 0.67 | POLB (0.35) | CES1DAGLAKDM4EGLAALDH1A1 | |
| SCHEMBL30586797 | 0.67 | CES1 (0.38) | CES1DAGLAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4934774 | 0.67 | FAAH (0.41) | CES1ALDH1A1 | |
| SCHEMBL26195949 | 0.64 | HSD17B1 (0.34) | KDM4EALDH1A1HPGD | |
| SCHEMBL29270430 | 0.62 | CES1 (0.37) | CES1KDM4ESMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | claimed |
| CN-111491918-A | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2020-08-04 | — | — | CN | claimed |
| US-8101799-B2 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES (US) | 2012-01-24 | — | — | US | claimed |
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | AGIOS PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-111491918-A | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2020-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | PAH, KDM8, PHF8 | TSHR 3622/4885CES1 1501/4885DAGLA 4641/4885 |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | TSHR 3622/4885CES1 1501/4885DAGLA 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.